gensci120
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 20, 2025 (NCT06827457)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07040930 | Phase 1 | Aug 1, 2025 | Fudan University, GeneScience Pharmaceuticals Co., Ltd. |
| NCT06827457 | Phase 1 | Feb 20, 2025 | GeneScience Pharmaceuticals Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeneScience Pharmaceuticals Co., Ltd. | For profit | 2 | 2 | 1 | 2025 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1